This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
by Ekta Bagri
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
by Zacks Equity Research
Atara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint.
Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock
by Zacks Equity Research
Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.
Karuna (KRTX) Posts Upbeat Safety Data on Schizophrenia Drug
by Zacks Equity Research
Data from an early-stage study shows that treatment with Karuna's (KRTX) KarXT was not associated with clinically meaningful increases in blood pressure in schizophrenia patients.
Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer
by Zacks Equity Research
Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.
Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.
Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.
Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
by Zacks Equity Research
Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.
Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication
by Zacks Equity Research
FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.
CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer
by Zacks Equity Research
If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.
The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics
by Zacks Equity Research
Pfizer, Allogene Therapeutics and Corcept Therapeutics are included in this Analyst Blog.
FDA Approves Pfizer's (PFE) Braftovi + Mektovi for Lung Cancer
by Zacks Equity Research
Pfizer's (PFE) Braftovi + Mektovi drug combo gets label expansion for BRAF V600E-mutant non-small cell lung cancer.
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
by Zacks Equity Research
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.
Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.
Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 10.17% and 38.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
by Zacks Equity Research
Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
by Zacks Equity Research
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
PepGen (PEPG) Down on Clinical Hold for DM1 Candidate
by Zacks Equity Research
PepGen (PEPG) shares fall after FDA places clinical hold on a study evaluating potential treatment for myotonic dystrophy.
J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH
by Zacks Equity Research
J&J (JNJ) submits a new drug application for a single tablet combination therapy of macitentan and tadalafil for the long-term treatment of pulmonary arterial hypertension.
Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval
by Zacks Equity Research
Lexicon's (LXRX) shares rise as it receives FDA approval for Inpefa, a once-daily oral tablet to treat a broad population of heart failure patients.
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
by Zacks Equity Research
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.